---
title: "Accretion Pharmaceuticals Ltd (ACCPL) — Share Price, Financials & Analysis"
symbol: "ACCPL"
company: "Accretion Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/ACCPL"
isin: "INE0T8T01010"
nse_symbol: "ACCPL"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 233.44
generated_at: "2026-09-13T19:21:05.611Z"
---

# Accretion Pharmaceuticals Ltd (ACCPL)

Canonical page: https://tapetide.com/stocks/ACCPL

## Company

- **NSE Symbol:** ACCPL
- **ISIN:** INE0T8T01010
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-05-21
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** accretionpharma.com

## About

Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]

## Latest Price

- **Price:** ₹215
- **Change:** +5 (+2.38%)
- **Open:** ₹207.6
- **Day High:** ₹215
- **Day Low:** ₹207.55
- **Previous Close:** ₹210
- **Volume:** 13200
- **As Of:** 2026-09-11T08:46:26+00:00

## Key Fundamentals

Observed at 2026-09-11T04:39:46.959883Z.

- **Market Cap:** ₹233.44 Cr
- **Classification:** SME
- **P/E (reported):** 24.1
- **Book Value:** ₹49.21
- **Price to Book:** 4.27
- **Dividend Yield:** 0%
- **ROE:** 44.44%
- **ROCE:** 67.28%
- **Debt to Equity:** 0.23
- **Revenue (yearly):** ₹89.63 Cr
- **Net Income:** ₹9.74 Cr
- **EBITDA:** ₹14.95 Cr
- **52-Week High:** ₹214.7
- **52-Week Low:** ₹53.8
- **RSI (14):** 61.55

## Tapetide Score

- **Score:** 56 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Average · Valuation: Expensive · Momentum: Rising
- **Percentile:** 74.1 (of 4473 scored stocks)
- **Confidence:** 86%
- **Data coverage:** 71%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 66.93 | 9% |
| growth | 94.25 | 9% |
| momentum | 98.9 | 12% |
| ownership | 66.3 | 24% |
| quality | 55.29 | 22% |
| valuation | 33.23 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has a good return on equity (ROE) track record: 3 Years ROE 35.3%

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | 149.96% | 34.03% | 552.76% |
| ebitda margin growth | -20.15% | -14.75% | — |
| net income growth | 43.24% | 549.33% | — |
| revenue growth | 55.88% | 88.42% | — |
| roce | 248.6% | 248.6% | — |
| roe | 63.5% | 35.81% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 13.35 | 18.56 | 38.81 | 43.74 | 45.89 |
| Expenses | 10.78 | 14.23 | 31.27 | 36.67 | 38.01 |
| Operating Profit | 2.57 | 4.33 | 7.54 | 7.07 | 7.88 |
| OPM % | 19.25 | 23.33 | 19.43 | 16.16 | 17.17 |
| Other Income | 0.05 | 0.02 | 0.08 | 0.11 | 0.08 |
| Interest | 0.4 | 0.69 | 0.74 | 0.37 | 0.48 |
| Depreciation | 0.22 | 0.37 | 0.41 | 0.4 | 0.81 |
| Profit before tax | 2 | 3.29 | 6.47 | 6.41 | 6.67 |
| Tax % | 25 | 25.23 | 33.08 | 25.9 | 26.24 |
| Net Profit | 1.49 | 2.46 | 4.33 | 4.75 | 4.92 |
| EPS in Rs | 3.72 | 3.01 | 5.3 | 4.27 | 4.43 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Sales | 13.35 | 57.38 | 89.63 |
| Expenses | 10.78 | 45.49 | 74.68 |
| Operating Profit | 2.57 | 11.89 | 14.95 |
| OPM % | 19.25 | 20.72 | 16.68 |
| Other Income | 0.05 | 0.09 | 0.19 |
| Interest | 0.4 | 1.44 | 0.85 |
| Depreciation | 0.22 | 0.77 | 1.21 |
| Profit before tax | 2 | 9.77 | 13.08 |
| Tax % | 25 | 30.4 | 26.15 |
| Net Profit | 1.49 | 6.79 | 9.67 |
| EPS in Rs | 3.72 | 8.31 | 8.7 |
| Dividend Payout % | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Equity Capital | 4 | 8.17 | 11.12 |
| Reserves | 1.49 | 7.12 | 43.59 |
| Borrowings | 13.48 | 14.1 | 12.32 |
| Other Liabilities | 8.47 | 10.48 | 9.63 |
| Total Liabilities | 27.44 | 39.87 | 76.66 |
| Fixed Assets | 5.25 | 6.09 | 13.21 |
| CWIP | 0 | 0 | 0.2 |
| Investments | 0 | 0 | 0 |
| Other Assets | 22.19 | 33.78 | 63.25 |
| Total Assets | 27.44 | 39.87 | 76.66 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Cash from Operating Activity | -11.51 | 5.75 | -14.62 |
| Cash from Investing Activity | -5.48 | -1.61 | -8.53 |
| Cash from Financing Activity | 17.08 | -4.18 | 27.12 |
| Net Cash Flow | 0.09 | -0.04 | 3.97 |
| Free Cash Flow | -16.99 | 4.14 | -23.15 |
| CFO/OP | -479 | 64 | -75 |

### Ratios

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Debtor Days | 158.58 | 74.17 | 91.22 |
| Inventory Days | 564.06 | 188.49 | 158.92 |
| Days Payable | 256.32 | 69.41 | 32.32 |
| Cash Conversion Cycle | 466.31 | 193.25 | 217.82 |
| Working Capital Days | 189.47 | 65.33 | 145.63 |
| ROCE % | — | 46.36 | 28.89 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2024 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Promoters | 100% | 73.5% | 73.52% | 73.52% | 73.52% | 73.52% |
| FIIs | 0% | 2.22% | 1.16% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 2.76% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 0% | 21.46% | 22.85% | 22.01% | 22.92% | 20.22% |
| Others | 0% | 2.82% | 2.47% | 4.47% | 3.56% | 3.5% |
| No. of Shareholders | 8 | 1628 | 1498 | 1179 | 1182 | 776 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 3 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 206.8 | Buy |
| EMA (10) | 206.7 | Buy |
| SMA (20) | 203.08 | Buy |
| EMA (20) | 201.27 | Buy |
| SMA (50) | 182.19 | Buy |
| EMA (50) | 183.66 | Buy |
| SMA (100) | 154.32 | Buy |
| EMA (100) | 158.95 | Buy |
| SMA (200) | 115.26 | Buy |
| EMA (200) | 129.21 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 64.44 | Neutral |
| MACD (12,26,9) | 7.93 | Sell |
| Stochastic (14,3,3) | 82.14 | Sell |
| ADX (14) | 32.62 | Buy |
| Williams %R (14) | 0 | Sell |
| ATR (14) | 6.99 | High Volatility |
| ROC (12) | 11.98 | Buy |
| Stoch RSI (14) | 91.18 | Sell |
| UO (7,14,28) | 60.64 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Sep - Postal ballot opens 10 Sep-9 Oct 2026 for MOA alteration, ₹500 crore borrowing limit, and security approvals. | [Shareholders meeting 9 Sep - Postal ballot opens 10 Sep-9 Oct 2026 for MOA alteration, ₹500 crore borrowing limit, and security approvals.](https://nsearchives.nseindia.com/corporate/APL2024_09092026202740_SEPBsigned.pdf) |
| 9 April 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written … | [Price movement 9 April 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …](https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=ACCPL&tabIndex=sme) |
| 8 May 2026 - On 8 May 2026, board approved FY26 audited results and appointed HR manager and auditors. | [Outcome of Board Meeting 8 May 2026 - On 8 May 2026, board approved FY26 audited results and appointed HR manager and auditors.](https://nsearchives.nseindia.com/corporate/APL2024_08052026160453_Outcome08052026signed.pdf) |
| 8 May 2026 - Board approved FY26 audited results, appointed HR Manager and auditors, and reported IPO proceeds utilization. | [Change in Auditors 8 May 2026 - Board approved FY26 audited results, appointed HR Manager and auditors, and reported IPO proceeds utilization.](https://nsearchives.nseindia.com/corporate/APL2024_08052026163017_Auditors.pdf) |
| 8 May 2026 - Board approved FY26 audited results and appointed HR, internal, and secretarial auditors. | [Appointment 8 May 2026 - Board approved FY26 audited results and appointed HR, internal, and secretarial auditors.](https://nsearchives.nseindia.com/corporate/APL2024_08052026161550_HRappt.pdf) |
| 7 May 2026 - Accretion Pharmaceuticals filed FY26 SDD compliance certificate; no non-compliance observed, two UPSI events captured. | [Structural Digital Database 7 May 2026 - Accretion Pharmaceuticals filed FY26 SDD compliance certificate; no non-compliance observed, two UPSI events captured.](https://nsearchives.nseindia.com/corporate/APL2024_07052026175738_IntimationSDDsigned.pdf) |
| 7 Jul - Accretion Pharmaceuticals confirms Regulation 27(2) non-applicability for quarter ended 30 June 2026 on NSE SME. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 7 Jul - Accretion Pharmaceuticals confirms Regulation 27(2) non-applicability for quarter ended 30 June 2026 on NSE SME.](https://nsearchives.nseindia.com/corporate/APL2024_07072026174943_IntimationCGNA30062026.pdf) |
| 7 January 2026 - SEBI order (07-Jan-2026) imposes Rs.1,00,000 penalty for IPO disclosure violation. | [Action(s) taken or orders passed 7 January 2026 - SEBI order (07-Jan-2026) imposes Rs.1,00,000 penalty for IPO disclosure violation.](https://nsearchives.nseindia.com/corporate/APL2024_07012026174228_IntimationSEsigned.pdf) |
| 7 April 2026 - Accretion Pharmaceuticals says Regulation 27(2) corporate governance report not applicable for quarter ended 31 March 2026. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 7 April 2026 - Accretion Pharmaceuticals says Regulation 27(2) corporate governance report not applicable for quarter ended 31 March 2026.](https://nsearchives.nseindia.com/corporate/APL2024_07042026133320_ExemptionCGSIGNED.pdf) |
| 6 July 2026 - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 6 July 2026 - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026.](https://nsearchives.nseindia.com/corporate/APL2024_06072026144644_SE74signed.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://nsearchives.nseindia.com/corporate/APL2024_22112025175609_IntimationTranscriptsigned.pdf) |
| May 2026 | [Concall - May 2026](https://nsearchives.nseindia.com/corporate/APL2024_15052026144826_Intimationpresentationsigned.pdf.) |

### Annual Reports

| Date | Document |
| --- | --- |
| from web | [Annual Report 2025 from web](https://nsearchives.nseindia.com/emerge/corporates/content/trampariya_17012025102852_DRHP_AccretionFinal.pdf) |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_30159_ACCPL_2025_2026_A_60498886_03082026193358.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28344_ACCPL_2024_2025_A_3961474_03092025195437.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:21:05.611Z.